Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 359

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 359
---
 a license agreement assigned from Valetudo Therapeutics LLC (“Valetudo”) on March 31, 2023, from a license between InnoBation Bio Co. Ltd (“InnoBation”) and Valetudo.

We were formed in Delaware on April 12, 2018.

Since our inception, our operations have focused on raising capital and entering into license and development agreements for conducting research and development activities for our products. We do not have any product candidates approved for sale and have not generated any revenue from product sales. We have funded our operations through the sale of equity, raising an aggregate of $4.5 million of gross proceeds from the sale of membership interests, and debt, issuing $10.0 million of bonds and $9.3 million of notes through September 30, 2024. Subsequent to September 30, 2024, the Company raised additional gross proceeds of $1.0 million of notes with Amantes, LLC, a related party of the Company.

Since our inception, we have incurred significant operating losses. Our net loss was $3.3 million and $4.2 million for each of the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of $28.4 million. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

•

conduct clinical trials for our CD47 product, as well as initiate and complete additional trials of future potential product candidates;

•

seek regulatory approval for any product candidates that successfully complete clinical trials;

•

scale up our clinical and regulatory capabilities;

•

manufacture materials for clinical trials or potential commercial sales;

•

establish a commercialization infrastructure and scale up manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval;

•

adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;

•

maintain, expand and protect our intellectual property portfolio;

•

hire additional clinical, manufacturing quality control, regulatory, manufacturing and scientific and administrative personnel;

•

add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and

•

incur additional legal, accounting and other expenses in operating as a public company.

### Proposed Business Combination
On November 30, 2022, we entered into a business combination agreement (the “Business Combination Agreement”), with Iris Acquisition Corp, a Delaware publicly traded special purpose acquisition company

<div align